Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

The US Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a once-daily pill, for adults with metastatic pancreatic adenocarcinoma, offering a new treatment option for patients with advanced pancreatic cancer.

Rasonque is a once-daily tablet that targets multiple forms of a protein called RAS, a key driver of tumor growth in most patients with pancreatic adenocarcinoma, which arises from cells lining the ducts of the pancreas.

The approval is for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” said Acting FDA Commissioner Kyle Diamantas, JD.

Pancreatic Cancer Remains Difficult To Treat

Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer

Pancreatic cancer has long been one of the toughest challenges in oncology. The five-year survival rate is around 13%, while recurrence rates approach 80% after treatment.

Approximately 90% to 95% of the 67,000 new pancreatic cancer cases diagnosed in the US each year are pancreatic adenocarcinoma, according to the National Cancer Institute.

Although pancreatic cancer represents roughly 3.2% of all cancer diagnoses, pancreatic adenocarcinoma accounts for a disproportionately high share of cancer deaths because of its typically late detection, aggressive disease course and historically limited treatment options.

However, daraxonrasib, developed by US-based late-stage clinical oncology company Revolution Medicines, has shown promise in improving survival among patients with metastatic pancreatic cancer.

What Is Daraxonrasib?

Daraxonrasib is a once-daily oral pill that demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.

The drug is described as a multi-selective inhibitor of RAS(ON) proteins and is the first approved drug in this new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.

Daraxonrasib works by blocking KRAS signaling proteins that drive tumour growth. Pancreatic cancer is considered one of the most RAS-driven cancers, with more than 90% of patients carrying tumo\rs driven by RAS protein mutations.

Who Can Take Daraxonrasib?

Read More: New Pancreatic Cancer Drug Daxaronrasib May Benefit Patients With Lung And Ovarian Tumors Too

The FDA approval is specifically for adults with metastatic pancreatic adenocarcinoma in two situations:

• Patients who have received at least one prior systemic therapy.
• Patients who are not candidates for multiagent systemic therapy.

Daraxonrasib Clinical Trial

In the Phase 3 clinical trial, including 500 adults, daraxonrasib led to a median overall survival of 13.2 months, compared

with 6.7 months with chemotherapy.

Daraxonrasib also significantly improved progression-free survival compared with chemotherapy. Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung and colon cancers.

What Are The Side Effects?

According to the company, daraxonrasib was generally well tolerated, with a manageable safety profile and no new safety signals. Prior studies with daraxonrasib have shown that rash is the most common side effect. Mouth sores, diarrhoea, nausea and vomiting have also been reported.

Pancreatic Cancer: Know The Warning Signs

Pancreatic cancer typically begins in the ducts of the organ and can rapidly spread to other parts of the body. Early-stage pancreatic tumours may not show up on imaging tests, making the disease difficult to diagnose until it has spread to other organs.

Prevention and early detection remain vital. Pancreatic cancer can often resemble common ailments, potentially delaying diagnosis.

Symptoms That Should Not Be Ignored

• Abdominal or back pain
• Unexplained weight loss
• Jaundice
• Changes in urine or stool
• New-onset diabetes
• Persistent fatigue.

Malaria Alert in Germany: Frankfurt Airport Worker Dies After Suspected ‘Mosquito Arrives on Plane’; 5 Infected

In an unusual case, an employee at Germany’s Frankfurt Airport has died from malaria, while five others have contracted the potentially serious infection after mosquitoes suspected of arriving on an aircraft were found at the airport.

The airport operator, Fraport, confirmed the employee’s death and said the five other infected people are receiving medical treatment.

Authorities have installed mosquito traps at the airport. Captured mosquitoes will be analysed in laboratories to determine their species and, where possible, establish their origin.

Fraport said its focus is now on information and prevention. Employees have been advised to seek medical attention if they develop malaria-like symptoms and to inform doctors that they work at the airport.

“Sadly, we must confirm that one employee has died as a result of the infection,” a Fraport spokesperson told the BBC.

The company said it had provided information to employees and urged them to consult a doctor if they develop symptoms.

What Happened?

According to Germany's Robert Koch Institute (RKI), four airport employees developed malaria between 4 and 6 July. The institute said mosquitoes were brought to the airport by aircraft from a malaria-endemic region in July.

Malaria transmission within Germany is extremely rare. The RKI says malaria cases in the country almost exclusively occur among people who have travelled to malaria-endemic areas.

The absence of a travel history can make diagnosis more difficult. A delayed diagnosis can increase the risk of severe disease.

The RKI also noted that the last airport-associated malaria case in Germany occurred at Frankfurt Airport in 2023.

What Is Malaria?

Malaria is a potentially life-threatening disease caused by Plasmodium parasites, which are transmitted to humans through the bites of infected female Anopheles mosquitoes.

Common symptoms include fever, chills and headache. More severe malaria can cause confusion, seizures, difficulty breathing and other life-threatening complications.

Symptoms generally begin around 10–15 days after the bite of an infected mosquito, although the timing can vary.

People at increased risk of severe malaria include young children, pregnant women, travellers without immunity and people with HIV/AIDS.

Malaria is not normally transmitted directly from person to person. However, transmission can occur through infected blood, including in rare circumstances through blood transfusion or contaminated needles.

Global Malaria Burden

According to the World Health Organization's World Malaria Report 2025, an estimated 282 million malaria cases and 610,000 deaths occurred worldwide in 2024 across 80 malaria-endemic countries.

The WHO African Region accounted for approximately 94% of global malaria cases and 95% of malaria deaths in 2024.

WHO estimates that malaria-prevention tools, including recommended vaccines and other interventions, helped avert approximately 170 million cases and 1 million deaths in 2024.

The report noted that WHO approved the world’s first malaria vaccines in 2021, and 24 countries have now added them to their regular immunisation schedules.

Despite the setbacks, there have been encouraging developments. So far, 47 countries and one territory have received malaria-free certification from WHO. Cabo Verde and Egypt were declared malaria-free in 2024, followed by Georgia, Suriname, and Timor-Leste in 2025.

COVID-19 is rising across the US again. Doctors have been reporting an increase in patients testing positive through the summer. But some physicians are noticing a change in how the illness is presenting.

Reports have emerged stating that COVID is resurfacing with new symptoms including nausea, vomiting and diarrhoea.

The CDC's latest respiratory illness data, updated August 21, shows that national and regional COVID-19 activity is increasing, although overall acute respiratory illness causing people to seek healthcare remains very low. COVID-19-related visits to the emergency room are also increasing.

Recent reports from doctors in Georgia describe patients arriving with gastrointestinal symptoms alongside, or sometimes instead of, the more familiar respiratory symptoms.

Nausea, Vomiting And Diarrhoea Are Uncommon COVID Symptoms

Although these symptoms may seem unusual compared with the classic COVID presentation, nausea, vomiting and diarrhoea are not new symptoms of COVID-19.

The CDC has included nausea, vomiting and diarrhoea among the possible symptoms of COVID-19 for years. What appears to be attracting attention now is that some doctors are seeing more patients presenting with these gastrointestinal symptoms during the current summer rise.

Dr James Black, medical director of emergency services at Phoebe Putney Memorial Hospital in Albany, Georgia, said doctors are still seeing fever, cough and upper-respiratory symptoms, but added, “A lot of people are coming in with gastrointestinal symptoms - nausea, vomiting, diarrhea, sometimes to the point of mild dehydration.”

Also read: Exclusive With Leading Pulmonologist: When Should You Worry About H1N1 Symptoms?

Why COVID Affects The Digestive System?

The digestive system contains ACE2 receptors, which the virus can use to enter cells. Infection and the body's inflammatory response can therefore contribute to symptoms like nausea, vomiting and diarrhoea.

Gastrointestinal symptoms can occur with respiratory symptoms or sometimes before them, which can make COVID harder to distinguish from stomach infections or food poisoning. That is why doctors say testing remains essential, especially when COVID is active in a certain area.

Also read: ‘Scromiting’: Cannabis-Linked Vomiting Cases Rising Again In US, Says CDC Report

What Are The Other Symptoms?

Doctors say people should not focus only on gastrointestinal symptoms. Common COVID symptoms include:

• Fever or chills
• Cough
• Sore throat
• Congestion or runny nose
• Fatigue
• Headache
• Muscle or body aches
• Shortness of breath
• Nausea or vomiting
• Diarrhoea

Also read: US CDC Says COVID ‘Growing’ In Nearly Every State: What You Should Know

When Should You Take A COVID Test?

If nausea, vomiting or diarrhoea occur alongside fever, cough, sore throat, congestion, fatigue or body aches, COVID should be considered, particularly when infections are increasing in the community. Testing can be especially important for people at higher risk of severe disease because antiviral treatment works best when started early.

Dr Gurinder Singh Sidhu, US antiviral medical lead and senior director at Pfizer, said, "People at higher risk should seek medical advice promptly rather than waiting for symptoms to become severe."

Severe vomiting or diarrhoea can also cause dehydration, so people should seek medical care if they cannot keep fluids down, are becoming unusually weak or dizzy, are urinating much less than usual, or develop breathing difficulties.